Sophocarpine alleviates non-alcoholic steatohepatitis in rats.
OBJECTIVE
Non-alcoholic steatohepatitis (NASH) is one entity in the spectrum of non-alcoholic fatty liver disease (NAFLD). The aim of this study was to explore the prevention and therapeutic effect of sophocarpine on experimental rat NASH.


METHODS
Sophocarpine with the dosage of 20 mg/kg/day was injected into NASH rats. At the end of 12 weeks, all rats were killed to detect the degree of fatty degeneration, inflammation and fibrosis.


RESULTS
Sophocarpine intervention (in the pro-treated and treated groups) resulted in a significant decrease of liver weight, liver index, serum transaminase and serum lipids. Messenger RNA expressions of leptin, interleukin (IL)-6, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β1, procollagen-I and α-smooth muscle actin (SMA) and deposition of IL-6, TNF-α and TGF-β1 in liver decreased, whereas the messenger RNA expression of adiponectin increased significantly compared with that in the model group. Moreover, histological improvement was also observed in the sophocarpine intervention group. In addition, there was no significant difference in any detected indicator between the pro-treated and treated group.


CONCLUSIONS
Sophocarpine could decrease the level of serum transaminase, improve lipid metabolism, reduce synthesis of inflammatory cytokines TNF-α, TGF-β1 and IL-6, activate protective adipocytokine adiponectin, and might be selected as a promising agent for the clinical prevention and therapy of NASH.
Department of Gastroenterology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.
Chun-Yan
CY
Song
Xin
X
Zeng
Si-Wen
SW
Chen
Ping-Fang
PF
Hu
Zhi-Wu
ZW
Zheng
Bei-Fang
BF
Ning
Jian
J
Shi
Wei-Fen
WF
Xie
Yue-Xiang
YX
Chen
D054392:Adipokines / Q000097:blood / Q000235:genetics; D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D016207:Cytokines / Q000097:blood / Q000235:genetics; D019610:Cytoprotection; D004195:Disease Models, Animal; D015536:Down-Regulation; D005234:Fatty Liver / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D018836:Inflammation Mediators / Q000097:blood; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D000093842:Matrines
D054392:Adipokines; D000470:Alkaloids; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D018836:Inflammation Mediators; D008055:Lipids; D000637:Transaminases; C035933:sophocarpine; D000093842:Matrines